Eris Lifesciences Limited (BOM:540596)
India · Delayed Price · Currency is INR 1,352.75
-22.85 (-1.66%)
At close: Jul 31, 2026
Eris Lifesciences Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
| 32,124 | 31,149 | 28,793 | 19,913 | 16,618 | 13,262 | |
Revenue Growth | 9.44% | 8.18% | 44.59% | 19.83% | 25.31% | 11.20% |
Cost of Revenue | 8,502 | 7,956 | 7,332 | 3,964 | 3,613 | 2,640 |
Gross Profit | 23,622 | 23,193 | 21,461 | 15,950 | 13,005 | 10,621 |
Selling, General & Admin | 5,658 | 5,568 | 5,261 | 4,137 | 3,548 | 2,622 |
Other Operating Expenses | 6,567 | 6,424 | 6,018 | 5,038 | 4,070 | 3,108 |
Operating Expenses | 15,036 | 14,787 | 14,434 | 11,005 | 8,789 | 6,376 |
Operating Income | 8,586 | 8,406 | 7,027 | 4,945 | 4,217 | 4,245 |
Interest Expense | -1,906 | -1,927 | -2,313 | -848 | -261.68 | -41.46 |
Interest & Investment Income | - | - | 50.6 | 70.1 | 22.99 | 60.98 |
Earnings From Equity Investments | -12 | 0.9 | 0.6 | - | - | - |
Currency Exchange Gain (Loss) | - | - | 0.9 | 18.6 | - | - |
Other Non Operating Income (Expenses) | 74.5 | 77.5 | 92.1 | 55.7 | 17.22 | 15.19 |
EBT Excluding Unusual Items | 6,742 | 6,558 | 4,858 | 4,241 | 3,995 | 4,280 |
Gain (Loss) on Sale of Investments | - | - | 39.8 | 93.8 | 71.32 | 166.09 |
Gain (Loss) on Sale of Assets | - | - | -9.2 | -21.4 | -20.05 | -42.54 |
Other Unusual Items | -172.4 | -172.4 | 0.2 | - | - | 18.68 |
Pretax Income | 6,569 | 6,385 | 4,889 | 4,313 | 4,046 | 4,422 |
Income Tax Expense | -88 | -89.7 | 1,142 | 342.2 | 304.83 | 364.09 |
Earnings From Continuing Operations | 6,657 | 6,475 | 3,747 | 3,971 | 3,742 | 4,058 |
Minority Interest in Earnings | -218.1 | -279.9 | -228.3 | -50.7 | 79.98 | 3.24 |
Net Income | 6,439 | 6,195 | 3,518 | 3,921 | 3,822 | 4,061 |
Net Income to Common | 6,439 | 6,195 | 3,518 | 3,921 | 3,822 | 4,061 |
Net Income Growth | 66.59% | 76.08% | -10.26% | 2.59% | -5.90% | 14.36% |
Shares Outstanding (Basic) | 137 | 137 | 136 | 136 | 136 | 136 |
Shares Outstanding (Diluted) | 137 | 137 | 136 | 136 | 136 | 136 |
Shares Change | 0.84% | 0.43% | 0.09% | - | 0.19% | 0.02% |
EPS (Basic) | 46.92 | 45.33 | 25.85 | 28.82 | 28.10 | 29.89 |
EPS (Diluted) | 46.85 | 45.26 | 25.81 | 28.79 | 28.07 | 29.88 |
EPS Growth | 65.23% | 75.36% | -10.35% | 2.56% | -6.06% | 14.31% |
Additional Metrics
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Free Cash Flow | - | 2,411 | 9,100 | 3,569 | -5,497 | 2,572 |
Free Cash Flow Per Share | - | 17.62 | 66.77 | 26.21 | -40.37 | 18.93 |
Dividend Per Share | - | 7.210 | 7.350 | - | 7.350 | 6.010 |
Dividend Growth | - | -1.91% | - | - | 22.30% | 9.27% |
Gross Margin | 73.53% | 74.46% | 74.53% | 80.10% | 78.26% | 80.09% |
Operating Margin | 26.73% | 26.99% | 24.40% | 24.83% | 25.37% | 32.01% |
Profit Margin | 20.04% | 19.89% | 12.22% | 19.69% | 23.00% | 30.62% |
Free Cash Flow Margin | - | 7.74% | 31.61% | 17.92% | -33.08% | 19.40% |
EBITDA | 11,324 | 11,201 | 10,047 | 6,625 | 5,259 | 4,827 |
EBITDA Margin | 35.25% | 35.96% | 34.90% | 33.27% | 31.65% | 36.40% |
D&A For EBITDA | 2,739 | 2,795 | 3,021 | 1,681 | 1,043 | 582.18 |
EBIT | 8,586 | 8,406 | 7,027 | 4,945 | 4,217 | 4,245 |
EBIT Margin | 26.73% | 26.99% | 24.40% | 24.83% | 25.37% | 32.01% |
Effective Tax Rate | - | - | 23.36% | 7.93% | 7.53% | 8.23% |
Revenue as Reported | 32,371 | 31,372 | 29,120 | 20,330 | 16,963 | 13,731 |
Advertising Expenses | - | - | 180.6 | 66.8 | 63.85 | 87.47 |